Contents

Adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE)

April 27, 2017

Clinical trial

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW.

N Engl J Med. 2017 Apr 27;376(17):1637-1646.
Full text | Metrics.

Main finding: Adalimumab was associated with a lower rate of treatment failure, but higher incidence of adverse events in children and adolescents with active JIA-associated uveitis on a stable dose of methotrexate

 

  • Purpose: Evaluate safety and efficacy of adalimumab in JIA-associated uveitis
  • Type: Randomized controlled Trial
  • Condition: JIA-associated uveitis

Participants: ≥2 years, active JIA-associated uveitis despite being on methotrexate and glucocorticoid therapy.

 

  • n=90

 

Intervention:

 

Group 1: Adalimumab (20mg or 40mg subcut every 2 weeks)
Group 2: Placebo

Both groups on a stable dose of weekly methotrexate.

Adalimumab Placebo
Treatment failure 27% 60%
All adverse events (events per patient-year) 10.07 6.51
Serious adverse events (events per patient-year) 0.29 0.19

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed